{"entity":{"id":"nct06997497","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","aka":["KANDLELIT-012"],"tldr":"A phase 3 trial testing Calderasib in colorectal cancer, now recruiting.","summary":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) is a phase 3 interventional study registered as NCT06997497, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Phase 3, Randomised, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012). Planned enrolment is 477 participants (estimated). The study started in 2025-07-16 and primary completion is expected in 2029-03-28. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06997497","url":"https://clinicaltrials.gov/study/NCT06997497"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal","kras-g12c-colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["calderasib"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06997497","phase":"3","setting":"A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)","sponsor":"Merck Sharp & Dohme","participation":[{"nct":"NCT06997497","source":"https://clinicaltrials.gov/study/NCT06997497","fetchedAt":"2026-10-07T16:55:20.203Z","studySha256":"c09106ecc32558e89ad0307c647ebdf86a69d2f55766aed7f74f98b5a25878b1","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-07","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":477,"enrolmentType":"ESTIMATED","siteCount":244,"recruitingSiteCount":244,"countries":["Argentina","Australia","Brazil","Canada","Chile","China","Colombia","Finland","France","Germany","Hong Kong","Hungary","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Philippines","Poland","Romania","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom","United States"]}],"started":"2025-07-16","startedType":"actual","enrolled":477,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06997497/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/"}],"drug":[{"id":"calderasib","kind":"drug","name":"Calderasib","route":"/drugs/calderasib/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}